Search | Clinical Trials Finder

Conditions: Cardiopulmonary Bypass, Inflammation, Fibrinolysis, Surgery
Interventions: HOE 140, Aminocaproic Acid, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT; Biological · Drug · Procedure
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: Up to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Frostbite
Interventions: Standard of care plus Epoprostenol infusion for 8 hours (hrs) per day up to 5 days maximum, Standard of Care + Placebo (Normal Saline)infusion for 8 hours per day up to 5 days maximum; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Radiation-induced Dermatitis
Interventions: ST266; Biological
Lead sponsor: Noveome Biotherapeutics, formerly Stemnion; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Rhytides
Interventions: PrabotulinumtoxinA-Xvfs, OnabotulinumtoxinA; Drug
Lead sponsor: Lupo Center for Aesthetic and General Dermatology; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Cardiac Arrest, Pulseless Electrical Activity
Interventions: High Calcium, Low Sodium (HCLS) Crystalloid Therapy, High Calcium, High Sodium (HCHS) Crystalloid Therapy; Drug
Lead sponsor: Carol Bernier; Other
Eligibility: 18 Years and older
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Cosmetic Surgery
Interventions: MIST Therapy, Standard Postoperative Incision Care; Device · Other
Lead sponsor: Celleration, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 3,440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lung Cancer (Diagnosis)
Interventions: Arm 1 "LipoB-I": Liposomal Bupivacaine via Multi-Level Intercostal Nerve Block, Arm 2 "LipoB-S": Liposomal Bupivacaine via Serratus Anterior Plane Block, Arm 3 "LipoB-C": Liposomal Bupivacaine Administered via Combination Block; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Lymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors
Interventions: Campath Purged Non-myeloablative ASCT, Donor Apheresis; Drug · Procedure
Lead sponsor: David Rizzieri, MD; Other
Eligibility: 17 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia
Interventions: Half normal saline, Low Dose rhCC10, High dose rhCC10; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 24 Weeks to 29 Weeks
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Boston, Massachusetts • Springfield, Massachusetts

Conditions: Kidney Diseases, Kidney Injury, Kidney Failure
Interventions: MB-102, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR); Drug · Device
Lead sponsor: MediBeacon; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Chicago, Illinois • Columbus, Ohio • Austin, Texas + 1 more

Conditions: Atrial Fibrillation, Alcohol
Interventions: Ethanol, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years to 81 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Respiratory Syncytial Virus Infections
Interventions: MEDI8897, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 0 Years to 1 Year
Enrollment: 3,012 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 66
States / cities: Birmingham, Alabama • Fort Defiance, Arizona • Fayetteville, Arkansas + 59 more

Conditions: Skin Aging of Face and Hands
Interventions: Platelet Rich Plasma; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 45 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Acute Pain
Interventions: Drug: Bupivacaine 0.375% 20 mL, Drug: Bupivacaine 0.375% diluted to 0.1875%; Drug
Lead sponsor: Anna Uskova; Other
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Degenerative Joint Disease, Osteoarthritis
Interventions: EACA, Placebo arm; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Coronary Artery Disease, Coronary Artery Stenoses, Valve Regurgitation, Mitral, Valve Regurgitation, Tricuspid
Interventions: Exparel Injectable Product, Bupivacaine Hydrochloride; Drug
Lead sponsor: Kathirvel Subramaniam; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Risk Reduction
Interventions: Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation, Placebo; Biological · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 49 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acquired Antithrombin Deficiency
Interventions: Human plasma derived antithrombin, Placebo; Drug
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 9
States / cities: Stanford, California • Miami, Florida • Boston, Massachusetts + 6 more

Conditions: Malaria, Malaria,Falciparum
Interventions: PfSPZ Vaccine, PfSPZ Challenge (7G8), Normal Saline; Biological · Other
Lead sponsor: Sanaria Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Asthma
Interventions: Magnesium Sulfate, Placebo; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 2 Years to 20 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Oxytocin, Placebo
Interventions: intranasal oxytocin, Placebo, Social support, No Social Support; Drug · Behavioral
Lead sponsor: Harvard School of Public Health (HSPH); Other
Eligibility: 22 Years to 65 Years
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Femoral Neck Fractures
Interventions: Tranexamic Acid, Placebo (saline); Drug
Lead sponsor: UConn Health; Other
Eligibility: 55 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Farmington, Connecticut • Hartford, Connecticut

Conditions: External Cephalic Version
Interventions: Intravenous Terbutaline, Intravenous Nitroglycerine; Drug
Lead sponsor: Yaakov Beilin; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Bradykinin Receptor Antagonism During Cardiopulmonary Bypass

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)

Study of ST266 Versus Saline in Treating Skin Irritation From Radiation

Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides

Surviving PEA in Roanoke (SPEAR) Study

Effectiveness Study of MIST Therapy After Cosmetic Surgery Procedures of the Face and Body

Combination Versus Alone Liposomal Bupivacaine Blocks in Minimally Invasive Thoracic Surgery-1

Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath

Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome

Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

The HOLIDAY (HOw ALcohol InDuces Atrial TachYarrhythmias) Study

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)

A Pilot Study on the Use of Platelet Rich Plasma (PRP) for Facial and Hand Skin Rejuvenation

Volume Versus Concentration: Clinical Effectiveness of Single Shot Quadrates Lumborum Block Using Either a High Volume/Low Concentration or Low Volume/High Concentration Injectate for Total Hip Arthroplasty.

Epsilon Aminocaproic Acid (EACA) for the Reduction of Blood Loss in Total Hip Arthroplasty (THA)

Comparison of Sternal Wound Infiltration With Liposomal Bupivacaine v. Bupivacaine Hydrochloride

Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease

Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI

Pilot Study of Magnesium Infusions in Pediatric Asthma

The Biology of Resilience

Topical (Intra-Articular) Tranexamic Acid and Transfusion Rates Following Hip Hemiarthroplasty

Study to Evaluate is ECV Success is Improved and the Side Effects Reduced With the Use of IV NTGL Versus Terbutaline